Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics

MLA

Tom M. Quinn, et al. “Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID Pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics.” EBioMedicine, vol. 76, no. 103856-, Feb. 2022. EBSCOhost, https://doi.org/10.1016/j.ebiom.2022.103856.

APA

Tom M. Quinn, Erin E. Gaughan, Annya Bruce, Jean Antonelli, Richard O’Connor, Feng Li, Sarah McNamara, Oliver Koch, Claire MacKintosh, David Dockrell, Timothy Walsh, Kevin G. Blyth, Colin Church, Jürgen Schwarze, Cecilia Boz, Asta Valanciute, Matthew Burgess, Philip Emanuel, Bethany Mills, … Kevin Dhaliwal. (2022). Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBioMedicine, 76(103856-). https://doi.org/10.1016/j.ebiom.2022.103856

Chicago

Tom M. Quinn, Erin E. Gaughan, Annya Bruce, Jean Antonelli, Richard O’Connor, Feng Li, Sarah McNamara, et al. 2022. “Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID Pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics.” EBioMedicine 76 (103856-). doi:10.1016/j.ebiom.2022.103856.